Biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed the care of patients with immune-mediated inflammatory diseases, characterized by common inflammatory pathways leading to inflammation, such as rheumatoid arthritis, spondyloarthritis, and inflammatory bowel disease. Biologic DMARDs improve symptoms and reduce structural damage of joints, the gastrointestinal tract, and other affected organs. Biologic DMARDs reduce disability, comorbidities, and mortality.1 However, many patients do not respond to treatment, and approximately 50% of initial responders subsequently have inadequate disease control, defined as secondary failure.2 Preventing secondary failure is an important therapeutic goal because disease flares are associated with irreversible tissue damage, glucocorticoid exposure, lost productivity, and worsened quality of life. Furthermore, it may take weeks to months to reestablish disease control after secondary failure.
Wallace ZS, Sparks JA. Therapeutic Drug Monitoring for Immune-Mediated Inflammatory Diseases. JAMA. 2021;326(23):2370–2372. doi:10.1001/jama.2021.21315
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.